PUL-042 is under clinical development by Pulmotect and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect PUL-042’s likelihood of approval (LoA) and phase transition for Chronic Obstructive Pulmonary Disease (COPD) took place on 03 Jun 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PUL-042 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

PUL-042 overview

PUL-042 is under development for the treatment of coronavirus disease 2019 (COVID-19) infections, rhinovirus induced symptoms in chronic obstructive pulmonary disease patients, SARS-associated coronavirus (SARS-CoV), MERS-associated coronavirus (MERS-CoV) and several other viral infections including anthrax, Influenza, Pneumococcus, Pseudomonas, Sendai Virus and unspecified cancer. The therapeutic candidate is formulated as an inhalational solution. It is a combination of two synthetic molecules, a lipopeptide (Pam2CSK4) and an oligodeoxynucleotide (ODN M362) that act on TLR2/6 and TLR9.

Pulmotect overview

Pulmotect is a biopharmaceutical company that develops host-directed and pathogen-agnostic drugs. The company’s technologies stimulate the body’s natural defences to offer broad-spectrum, fast-acting protection against bacterial pneumonia, fungal pneumonia, influenza, and others. It offers PUL-042 is an inhaled therapeutic that stimulates the innate immune system in minutes to provide immediate and effective protection against major classes of pathogens. Pulmotect’s products reduce morbidity and mortality in patients at risk of severe respiratory diseases. It undertakes clinical trials for various drugs. Pulmotect is headquartered in Houston, Texas, the US.

Quick View PUL-042 LOA Data

Report Segments
  • Innovator
Drug Name
  • PUL-042
Administration Pathway
  • Inhalational
Therapeutic Areas
  • Infectious Disease
  • Oncology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.